BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIVI BioVie Inc

Closed Labor Day 09-04 16:00:00 EDT

2.00

-0.03

-1.48%

盘后2.00

+0.00-0.01%

19:58 EDT

High2.08	Low1.96	Vol296.76K
Open2.04	D1 Closing2.03	Amplitude5.91%
Mkt Cap16.90M	Tradable Cap16.82M	Total Shares8.45M
T/O597.60K	T/O Rate3.53%	Tradable Shares8.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIVI","market":"US","secType":"STK","nameCN":"BioVie Inc","latestPrice":2,"timestamp":1788552000000,"preClose":2.03,"halted":0,"volume":296762,"hourTrading":{"tag":"盘后","latestPrice":1.9997,"preClose":2,"latestTime":"19:58 EDT","volume":24457,"amount":48420.0412,"timestamp":1788566300295,"change":-0.0003,"changeRate":-0.00015,"amplitude":0.02},"delay":0,"changeRate":-0.014778325123152615,"floatShares":8409800,"shares":8451148,"eps":-3.049999,"marketStatus":"Closed Labor Day","change":-0.03,"latestTime":"09-04 16:00:00 EDT","open":2.04,"high":2.08,"low":1.96,"amount":597602.6672518001,"amplitude":0.059113,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.049999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.03,"preHourTrading":{"tag":"盘前","latestPrice":2.07,"preClose":2.03,"latestTime":"09:26 EDT","volume":8406,"amount":17215.733455200003,"timestamp":1788528402591,"change":0.04,"changeRate":0.019704,"amplitude":0.02936},"postHourTrading":{"tag":"盘后","latestPrice":1.9997,"preClose":2,"latestTime":"19:58 EDT","volume":24457,"amount":48420.0412,"timestamp":1788566300295,"change":-0.0003,"changeRate":-0.00015,"amplitude":0.02},"volumeRatio":0.4504071333507688,"impliedVol":1.6378,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BIVI","defaultTab":"news","newsList":[{"id":"2663008114","title":"BioVie Completes Treatment Phase of Phase 2 Long COVID Trial for Bezisterim","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008114","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008114?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:05","pubTimestamp":1788177947,"startTime":"0","endTime":"0","summary":"BioVie completes treatment phase of Phase 2 Long COVID trial for bezisterimBioVie completed the treatment phase of its Phase 2 ADDRESS-LC trial of bezisterim for neurological Long COVID symptoms.Topli","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL16GfyF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","BK4112","IE00BQXX3D17.EUR","SG9999014021.USD","SG9999014039.USD","SG9999014013.SGD","BK4139","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BIVI","BK4588","LU2095319765.USD","BCDF","NDAQ","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","BK4585","LU0314104364.USD","SG9999014005.SGD","IE00BQXX3C00.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008643","title":"BioVie - Topline Results for Address-Lc Expected Before End of September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008643","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008643?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUA6QMMVV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008528","title":"BioVie Announces Completion of Treatment Phase of Address-Lc Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long Covid","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008528?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUA6QMMVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663197350","title":"BioVie President and CEO Cuong V Do Acquires 15,210 Shares Worth $31,637.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2663197350","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663197350?lang=en_us&edition=fundamental","pubTime":"2026-08-29 08:58","pubTimestamp":1787965103,"startTime":"0","endTime":"0","summary":"BioVie President and CEO Cuong V Do acquires 15,210 shares worth $31,637.68BioVie President and CEO Cuong V Do bought 15,210 common shares in open-market purchases at a weighted-average price of $2.08","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260829:nNDL3FTc7l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioVie President and CEO Cuong V Do Acquires 15,210 Shares Worth $31,637.68","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660444713","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2660444713","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660444713?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:11","pubTimestamp":1787137912,"startTime":"0","endTime":"0","summary":"Rising Dragon Acquisition  shares were up more than 198% in Wednesday's premarket activity following a 0.7% gain in the previous session.Tenon Medical  stock was up 85% after closing 11% higher at Tuesday's close.Zeta Network Group  shares were up 63% following a 5.2% increase at Tuesday's close.BioVie  stock was 57% higher, recovering from the previous session's 18% loss.FreeCast  shares were up 25% following a 144% rise on Tuesday when the company said it acquired full control of Investor News Channel and plans to relaunch it as a 24/7 global Free Ad-Supported Streaming Television network slated for November.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CAST","BK4139","BIVI","BK4204","BK4108","TNON","BK4082","RDAC","ZNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659153221","title":"BioVie Q4 EPS $(0.70) Up From $(1.42) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2659153221","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659153221?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:29","pubTimestamp":1786616946,"startTime":"0","endTime":"0","summary":"BioVie (NASDAQ:BIVI) reported quarterly losses of $(0.70) per share. This is a 50.7 percent increase over losses of $(1.42) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61167611/biovie-q4-eps-0-70-1-42-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQM","QLD",".IXIC","QQQA","TECS","QQQE","QQQ","GPIQ","IYW","ONEQ","NQmain","MNQmain","BK4139","QQQJ","NVIW.SI","TQQQ","TQQY","PSQ","QID","QYLG","QQQY","BIVI","FTEC","NDX","QDTE","SQQQ","JEPQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659015803","title":"BioVie FY26 Net Loss Widens to $22.1 Million; Operating Expenses Rise to $22.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659015803","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659015803?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:05","pubTimestamp":1786615512,"startTime":"0","endTime":"0","summary":"BioVie FY26 net loss widens to $22.1 million; operating expenses rise to $22.7 millionBioVie posted a net loss of USD 22.1 million, widening from USD 17.5 million a year earlier.Operating expenses ros","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL4Jtg4j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659092299","title":"U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2659092299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659092299?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:17","pubTimestamp":1786551433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sutro Biopharma, HumacyteAugust 12 (Reuters)-Wall Street's main indexes rose on Wednesday, with the Nasdaq outperforming peers as upbeat earnings from AI infrastructure fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL6N4490YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","SMCI","CIEN","SMCL","HRB","CORD","WXM","CAVA","HUMA","NBIZ","TPL","ABSI","LQDA","FSLR","OFAL","SLN","SVV","O","DPRE","BETA","SLXN","NBIS","ANNX","CRWV","LOCL","SLNCF","TRMB","UAMY","NBIX","ALT","EAT","STRO","DFTX","LITE","UFO","EGGY","NCMI","OPLN","SMMT","BIVI","EROC","PFGC","SMWB","TAN","CHTR","LAZR","TSHA","GAP","TECH","LUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908203","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:47 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908203","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908203?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:47","pubTimestamp":1786542437,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:47 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nAQN2MECLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636873","title":"BioVie Posts Corporate Presentation Outlining Bezisterim and Biv201 Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636873","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636873?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:59","pubTimestamp":1786017589,"startTime":"0","endTime":"0","summary":"BioVie posts corporate presentation outlining bezisterim and BIV201 clinical programsBioVie highlighted bezisterim, an oral, blood-brain barrier-penetrating small molecule targeting TNFα-driven inflam","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL305QDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657581635","title":"BioVie Says Phase 2 Sunrise-PD Trial Shows Bezisterim Improves Motor and Non-Motor Symptoms in Early Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2657581635","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657581635?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:36","pubTimestamp":1786016193,"startTime":"0","endTime":"0","summary":"BioVie says Phase 2 SUNRISE-PD trial shows bezisterim improves motor and non-motor symptoms in early Parkinson’s diseaseBioVie reported topline Phase 2 SUNRISE-PD results for bezisterim in early Parki","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8ZC7rp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633476","title":"BioVie - Bezisterim Well Tolerated with Safety Profile Comparable to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633476?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA5XZRKD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633273","title":"BioVie - Bezisterim Shows Statistically Significant Improvements in Motor and Non-Motor Symptoms vs Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633273?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA5XZRKD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633225","title":"BioVie Announces Topline Results of Phase 2 Sunrise-Pd Trial of Bezisterim in Early Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633225","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633225?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA5XZRKD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657332146","title":"BioVie - Bezisterim Reduces Biomarkers of Neurodegeneration and Inflammation","url":"https://stock-news.laohu8.com/highlight/detail?id=2657332146","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657332146?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA5XZRKD:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657290633","title":"BioVie - Phase 2 Trial Meets Prespecified Endpoints with Bezisterim Improving Inflammatory and Biological Markers","url":"https://stock-news.laohu8.com/highlight/detail?id=2657290633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657290633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:30","pubTimestamp":1786015802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA5XZRKD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644034506","title":"BRIEF-Biovie Files To Offer Up To $300 Million In Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644034506","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644034506?lang=en_us&edition=fundamental","pubTime":"2026-06-19 06:34","pubTimestamp":1781822058,"startTime":"0","endTime":"0","summary":"BRIEF-Biovie Files To Offer Up To $300 Million In Securities - SEC FilingJune 18 (Reuters) - BioVie Inc BIVI.O:BIOVIE - FILES TO OFFER UP TO $300 MILLION IN SECURITIES - SEC FILINGSource text: [ID:n0001520138-26-000244]Further company coverage: BIVI.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q137:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644803141","title":"BioVie Files $300 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2644803141","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644803141?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:46","pubTimestamp":1781819203,"startTime":"0","endTime":"0","summary":"BioVie  filed a shelf registration statement with the US Securities and Exchange Commission Thursday for the potential sale of up to $300 million of securities from time to time in one or more offerings.The filing covers class A common stock, preferred stock, warrants, debt securities, rights and units.The company intends to use the net proceeds for general corporate purposes.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644903117","title":"BioVie files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2644903117","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644903117?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:25","pubTimestamp":1781817909,"startTime":"0","endTime":"0","summary":"17:23 EDT BioVie (BIVI) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biovie-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biovie-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIVI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644532031","title":"BioVie - Files to Offer up to $300 Mln in Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644532031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644532031?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:22","pubTimestamp":1781817725,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nFWN42Q137:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioviepharma.com","stockEarnings":[{"period":"1week","weight":-0.0741},{"period":"1month","weight":-0.0196},{"period":"3month","weight":0.25},{"period":"6month","weight":0.4706},{"period":"1year","weight":0.2579},{"period":"ytd","weight":0.7241}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.005325},{"month":2,"riseRate":0.5,"avgChangeRate":0.259645},{"month":3,"riseRate":0.625,"avgChangeRate":-0.036628},{"month":4,"riseRate":0.375,"avgChangeRate":0.025089},{"month":5,"riseRate":0.222222,"avgChangeRate":-0.110348},{"month":6,"riseRate":0.555556,"avgChangeRate":0.426902},{"month":7,"riseRate":0.444444,"avgChangeRate":0.260814},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.130957},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.158174},{"month":10,"riseRate":0.375,"avgChangeRate":0.201324},{"month":11,"riseRate":0.5,"avgChangeRate":-0.005666},{"month":12,"riseRate":0.25,"avgChangeRate":-0.131533}],"exchange":"NASDAQ","name":"BioVie Inc","nameEN":"BioVie Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioVie Inc(BIVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioVie Inc,BIVI,BioVie Inc股票,BioVie Inc股票老虎,BioVie Inc股票老虎国际,BioVie Inc行情,BioVie Inc股票行情,BioVie Inc股价,BioVie Inc股市,BioVie Inc股票价格,BioVie Inc股票交易,BioVie Inc股票购买,BioVie Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioVie Inc(BIVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction